Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

Inclusion Criteria

• •1. Must be able to read and understand the informed consent form (ICF) and follow protocol requirements
• •2. Patients aged\>=18 years
• •3. Patients with renal cell carcinoma, Transitional cell carcinoma, non small cell lung cancer, and hepatocellular carcinoma
• •4. Patients treated with PD-1/PDL-1 inhibitors
• •5. Patients prior to first cycle of PD-1/PDL-1 inhibitors
• •6. Subjects willing to continue and take part in the study for the throughout the study duration.